Search
for
Sort by
Research 31–60 of 248
- Exosomes for repair, regeneration and rejuvenation
- TGF-β family signaling in stem cells
- Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy
- Methotrexate in dermatology
- Repurposing of approved cardiovascular drugs
- Electrospun Nanofibers for Improved Angiogenesis: Promises for Tissue Engineering Applications
- Nutrition and hair
- Physiological and pharmacological features of the non-saponin components in Korean Red Ginseng
- Telogen effluvium
- THE DISEASE SPECTRUM, EPIDEMIOLOGY, AND ETIOLOGY OF TOXIC-SHOCK SYNDROME
- The Clinical Presentation of Systemic Lupus Erythematosus
- ANDROGENETIC ALOPECIA
- Hormonal therapies for acne
- Guidelines for the Use of Acitretin in Psoriasis
- Postmenopausal virilization after spousal use of topical androgens
- The Transmembrane Serine Protease HAT-like 4 Is Important for Epidermal Barrier Function to Prevent Body Fluid Loss
- Promotion Effect of Apo-9′-fucoxanthinone from <i>Sargassum muticum</i> on Hair Growth <i>via</i> the Activation of Wnt/β-Catenin and VEGF-R2
- Medical Treatment of Hepatocellular Carcinoma: Any Progress?
- Spironolactone and XPB: An Old Drug with a New Molecular Target
- Phytochemistry and pharmacological studies of Plumbago zeylanica L.: a medicinal plant review
- Case 21-2012
- Skin diseases in consequence of endocrine alterations
- Optimization and Characterization of <i>Cuscuta reflexa </i>Extract Loaded Phytosomes by the Box-Behnken Design to Improve the Oral Bioavailability
- Niosomes as Carrier in Dermal Drug Delivery
- Targeted expression of SV40 T antigen in the hair follicle of transgenic mice produces an aberrant hair phenotype
- An ovarian Leydig cell tumor of ultrasound negative in a postmenopausal woman with hirsutism and hyperandrogenism
- Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs
- Clinical Development of Topoisomerase-Interactive Drugs
- Abiraterone and spironolactone in prostate cancer: a combination to avoid
- Controversies in off‐label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies